Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

pCR Rate × Docetaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 483 Carcinoma, Non-Small-Cell Lung 437 Prostatic Neoplasms 291 Lung Neoplasms 170 Stomach Neoplasms 140 Neoplasms 114 Squamous Cell Carcinoma of Head and Neck 108 Neoplasm Metastasis 97 Head and Neck Neoplasms 95 Esophageal Neoplasms 71 Ovarian Neoplasms 57 Pancreatic Neoplasms 42 Urinary Bladder Neoplasms 39 Sarcoma 39 Nasopharyngeal Carcinoma 36 Carcinoma, Squamous Cell 30 Triple Negative Breast Neoplasms 28 Carcinoma, Ovarian Epithelial 28 Adenocarcinoma of Lung 27 Adenocarcinoma 27 Esophageal Squamous Cell Carcinoma 25 Parkinson Disease 4, Autosomal Dominant Lewy Body 23 Carcinoma, Transitional Cell 23 Adenocarcinoma Of Esophagus 23 Breast Neoplasms, Male 22 Recurrence 21 Unspecified Adult Solid Tumor, Protocol Specific 20 Inflammatory Breast Neoplasms 20 Fallopian Tube Neoplasms 20 Melanoma 18

Interventions

Metformin 1 Epirubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01929811 2022-04-06

NeoMET

Shanghai Jiao Tong University School of Medicine

Phase 2 Terminated

pCR Rate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡